Altimmune, Inc. ALT
We take great care to ensure that the data presented and summarized in this overview for Altimmune, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALT
View all-
Black Rock Inc. New York, NY5.32MShares$48 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$45 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$35 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$30.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$24.8 Million1.44% of portfolio
-
Geode Capital Management, LLC Boston, MA1.67MShares$15.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.3MShares$11.7 Million0.0% of portfolio
-
Knoll Capital Management, LLC Miami, FL1.12MShares$10.1 Million3.4% of portfolio
-
Goldman Sachs Group Inc New York, NY933KShares$8.42 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA927KShares$8.37 Million0.0% of portfolio
Latest Institutional Activity in ALT
Top Purchases
Top Sells
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Insider Transactions at ALT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2024
|
David Drutz Director |
SELL
Open market or private sale
|
Indirect |
16,011
-14.28%
|
$96,066
$6.91 P/Share
|
|
Aug 19
2024
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,750
+27.06%
|
$83,500
$2.55 P/Share
|
|
Jul 31
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
650
+1.48%
|
$3,250
$5.41 P/Share
|
|
Jul 31
2024
|
Andrew Shutterly Acting Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,259
+9.97%
|
$6,295
$5.41 P/Share
|
|
Jul 31
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,486
+2.63%
|
$7,430
$5.41 P/Share
|
|
Jul 31
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
917
+5.89%
|
$4,585
$5.41 P/Share
|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,376
-2.79%
|
$75,384
$9.32 P/Share
|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+5.93%
|
-
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,332
-4.17%
|
$20,988
$9.32 P/Share
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+12.2%
|
-
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,330
-5.18%
|
$20,970
$9.32 P/Share
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+14.74%
|
-
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,313
-2.53%
|
$65,817
$9.88 P/Share
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+5.42%
|
-
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-3.6%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+10.98%
|
-
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-4.62%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+13.65%
|
-
|
|
Jan 31
2024
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,621
+9.31%
|
$9,242
$2.69 P/Share
|
|
Jan 31
2024
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,889
+2.82%
|
$15,778
$2.69 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 31K shares |
|---|---|
| Exercise of conversion of derivative security | 182K shares |
| Payment of exercise price or tax liability | 48.8K shares |
|---|---|
| Open market or private sale | 16K shares |